A Phase I Trial to Evaluate the Pharmacokinetics, Safety and Immunogenicity of Subcutaneously Administered Biosimilar SCB-808 and Originator Drug Enbrel in Healthy Volunteers

Trial Profile

A Phase I Trial to Evaluate the Pharmacokinetics, Safety and Immunogenicity of Subcutaneously Administered Biosimilar SCB-808 and Originator Drug Enbrel in Healthy Volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Aug 2018

At a glance

  • Drugs Etanercept (Primary)
  • Indications Autoimmune disorders; Psoriasis; Rheumatoid arthritis
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Clover Biopharmaceuticals
  • Most Recent Events

    • 01 Aug 2018 According to a Clover Biopharmaceuticals media release, the first patient from this trial has been dosed.
    • 01 Aug 2018 Status changed from planning to recruiting, according to a Clover Biopharmaceuticals media release.
    • 28 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top